Topics
Glioblastoma | Prognosis | Overall survival
Home > Publications > Topics > Glioblastoma > Prognosis > Overall survival
Gendreau
J, Mehkri Y, Kuo C, Chakravarti S, Jimenez MA, Shalom M, Kazemi F,
Mukherjee D.
Clinical
Predictors of Overall Survival in Very Elderly Patients With
Glioblastoma: A National Cancer Database Multivariable Analysis.
Neurosurgery.
2024 Jun 28. doi:
10.1227/neu.0000000000003072. PMID:
38940573. Observational study˰ ˍ
Habibi MA, Ghorbani M, Esmaeilian S, Tajvidi F, Nekutalaban P,
Boskabadi AR, Alemi F, Zafari R, Mirjani MS, Eazi S, Minaee P.
Stereotactic radiosurgery versus
combined stereotactic radiosurgery and bevacizumab for recurrent
glioblastoma; a systematic review and meta-analysis of survival.
Neurosurg
Rev. 2024 Jul 13;47(1):323. doi:
10.1007/s10143-024-02585-9. PMID:
39002028. Review; Meta-analysis˰
ˍ
*Harter PN, Weber KJ, Ricklefs FL, Drexler R, Schüller U,
Hack M, Hanke T, Dohmen H, Acker T, von Deimling A, Hasselblatt M,
Divé I, Unger K, Steinbach JP, Capper D, Ronellenfitsch MW.
Survival probability of epigenetically
defined IDH-wild-type glioblastoma without necrosis or vascular
proliferation.
Neurooncol
Adv. 2024 Aug 2;6(1):vdae138. doi:
10.1093/noajnl/vdae138. PMID:
39184173. Observational study. ˍ
Snider S, De Domenico P, Roncelli F, Bisoglio A, Braga M, Ghelfi
A, Barzaghi LR, Mura C, Mortini P, Gagliardi F.
Pre-operative
mean platelet volume is associated with overall survival in
patients with IDH-wildtype glioblastoma undergoing maximal safe
resection.
Oncol
Lett. 2024 Sep 30;28(6):576. doi:
10.3892/ol.2024.14709. PMID:
39397801. Observational study. ˍ
Alirezaei Z, Amouheidari A, BasirianJahromi R, Seyyedhosseini S,
Hamidi A.
Survival Analysis of
Glioblastoma: A Scientometric Perspective.
World
Neurosurg. 2024 Nov 20:S1878-8750(24)01919-3? doi:
10.1016/j.wneu.2024.11.059? PMID:
39577630. Bibliometric analysis˰
ˍ
Karnofsky Performance Status
Ohba S, Teranishi T, Matsumura K, Kumon M, Kojima D, Fujiwara E,
Nakao K, Kuwahara K, Murayama K, Pareira ES, Yamada S, Joko M,
Nakae S, Muto J, Nishiyama Y, Adachi K, Sasaki H, Abe M, Hasegawa
M, Hirose Y.
Factors involved in
maintaining Karnofsky Performance Status (≥ 50%) in
glioblastoma, IDH-wildtype patients treated with temozolomide and
radiotherapy.
Sci
Rep. 2025 Jan 11;15(1):1750. doi:
10.1038/s41598-025-85339-x. PMID:
39799218. Observational study. ˍ
Artificial intelligence
Maragno E, Ricchizzi S, Winter NR, Hellwig SJ, Stummer W, Hahn T,
Holling M.
Predictive modeling with
linear machine learning can estimate glioblastoma survival in
months based solely on MGMT-methylation status, age and sex.
Acta
Neurochir (Wien). 2025 Feb 24;167(1):52. doi:
10.1007/s00701-025-06441-7. PMID:
39992425. Observational study. ˍ
Epilepsy.
Presentation
Demetz M, Hecker C, Salim HA, Krigers A, Steinbacher J, Machegger
L, Kerschbaumer J, Buchta M, Pöppe J, Geiger P, Spinello A,
Kraus TFJ, Griessenauer CJ, Thomé C, Freyschlag CF,
Schwartz C.
Epilepsy as primary tumor
manifestation correlates
with patient status, age, and tumor volume but not with survival
in elderly
glioblastoma patients: a retrospective bicentric analysis.
Neurosurg
Rev. 2025 Feb
24;48(1):264. doi:
10.1007/s10143-025-03397-1. PMID:
39994084. Observational study. ˍ